查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1625427

CAR-T细胞疗法市场，规模，占有率，趋势，产业分析报告:各适应症，标的抗原，各地区 - 市场预测，2025年～2034年

CAR-T Cell Therapy Market Size, Share, Trends, Industry Analysis Report: By Indication, Target Antigen, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，预计到 2034 年，全球 CAR-T 细胞治疗市场规模将达到 1888.4 亿美元。该报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

嵌合抗原受体 T 细胞 (CAR-T) 疗法代表了癌症治疗的进步，并彻底改变了免疫肿瘤学。这种治疗是个人化的，透过改造患者的 T 细胞来表达针对特定癌症抗原的合成受体，对特定癌症（特别是血液系统恶性肿瘤）非常有效，从而提供了广泛的治疗选择。在生物技术的快速进步、CAR-T疗法批准率的提高以及对创新癌症治疗的需求不断增长的推动下，全球CAR-T细胞疗法市场在过去十年中经历了快速增长。

全球癌症发生率不断上升，以及对精准医疗的日益青睐，推动了对 CAR-T 细胞疗法等先进疗法的需求。此外，支持性监管框架和加速审批途径正在加速 CAR-T 疗法的上市。政府和私人研究投资正在进一步推动CAR-T细胞治疗市场的扩张。

下一代 CAR-T 疗法（包括多标靶 CAR-T 细胞和装甲 CAR-T 细胞）的发展正在推动 CAR-T 细胞疗法市场的成长。多标靶 CAR-T 细胞旨在识别多种抗原，解决肿瘤异质性和抗原逃脱等限制传统 CAR-T 治疗有效性的问题。武装CAR-T细胞旨在透过分泌细胞激素和其他分子来克服免疫抑制的肿瘤微环境，从而增强抗肿瘤活性。

CAR-T 疗法的应用正在扩展到肿瘤学之外。研究人员正在探索其治疗狼疮和多发性硬化症等自体免疫疾病以及爱滋病毒等传染病的潜力。这些新应用预计将显着扩大市场范围和影响力。

CAR-T 细胞治疗市场报告亮点

有迹象表明，滤泡性淋巴瘤 (FL) 领域预计将以最快的速度增长，在预测期内复合年增长率为 43.2%。

基于标靶抗原，CD19/CD22抗原片段在瀰漫性大B细胞淋巴瘤（DLBCL）和急性淋巴性白血病（ALL）等B细胞恶性肿瘤的治疗中具有明确的作用并受到重视。达到62585亿美元，占最大市场占有率。

在全球市场中，2024年北美CAR-T细胞治疗市场占47.16%的市占率。这是由于先进的医疗基础设施、高研发投资和血液恶性肿瘤的高盛行率。

由于復发性或难治性血癌盛行率上升以及人们越来越关注扩大先进治疗的可及性，欧洲CAR-T 细胞治疗市场将在预测期内增长，预计复合年增长率为33.2 %。

作为全球主要市场企业的一个例子，Bluebird Bio，Celgene Corporation，Gilead Sciences，Cellectis，Servier Laboratories，Pfizer Inc.，Merck，Amgen，Intellia Therapeutics，Novartis，Caribou Biosciences，Celyad，Bellicum Pharmaceuticals，Noile-Immune Biotech，南京市 Legend Biotechnology Co.等能举出(举行)。

目录

第1章 简介

  • 报告的说明
    • 研究的目的
    • 市场范围
  • 前提条件
  • 利害关係者
  • 简称一览

第2章 摘要整理

  • 市场概况

第3章 调查手法

  • 概要
    • 资料探勘
  • 资料来源
    • 一次资讯
    • 二次资讯

第4章 CAR-T细胞疗法市场洞察

  • CAR-T细胞疗法市场动态
    • 促进因素和机会
      • 白血病领域前景广阔，DLBCL 和多发性骨髓瘤新药上市
      • 应用于实体肿瘤的可能性
    • 阻碍因素与课题
      • 患者復发
      • 製造与物流课题
      • 经济模型/报销/扩展
  • PEST分析
  • CAR-T细胞疗法开发时间表
  • CAR-T细胞製造的前景
  • CAR-T细胞的副作用
  • 针对实体瘤的抗原
  • CAR-T临床试验状况
  • 商业格局（併购、伙伴关係和合作）
  • CAR-T疗法的新创新
    • "现成的" CAR-T 或类似的 CAR-T
    • 双 CAR-T 开发
    • 非病毒转录技术的发展
    • TIL 和 TCR 疗法的出现
      • TCR（T 细胞受体）
      • TIL（肿瘤浸润淋巴球）
  • 电晕影响分析
  • 客製化 - CAR-T 细胞市场

第5章 CAR-T细胞疗法市场评估:各适应症

  • 简介
  • DLBCL
  • ALL
  • CLL
  • MM
  • FL
  • 肥胖细胞症
  • 骨髓纤维化
  • MLLL
  • 胸腺癌症
  • 神经胶母细胞瘤
  • AML
  • 其他的适应症

第6章 全球CAR-T细胞疗法市场:标的抗原

  • 简介
  • CD19/CD22
  • BCMA
  • 其他

第7章 CAR-T细胞疗法市场评估:各地区

  • 简介
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 奥地利
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
  • 南美
    • 巴西
    • 墨西哥
  • 中东·非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国

第8章 竞争情形

  • 产品的销售和收购是被企业最僱用的策略
  • 产品销售
  • 联盟/合作/协定/公开

第9章 企业简介

  • Bluebird Bio
    • 公司概要
    • 财务实际成果
    • 产品基准
    • 最近的开发
  • Celgene Corporation
    • 公司概要
    • 财务实际成果
    • 产品基准
    • 最近的开发
  • Gilead Sciences, Inc.
    • 公司概要
    • 财务实际成果
    • 产品基准
    • 最近的开发
  • Cellectis
    • 公司概要
    • 财务实际成果
    • 产品基准
    • 最近的开发
  • Servier Laboratories
    • 公司概要
    • 财务实际成果
    • 产品基准
    • 最近的开发
  • Pfizer Inc.
    • 公司概要
    • 财务实际成果
    • 产品基准
    • 最近的开发
  • Merck KGaA
    • 公司概要
    • 财务实际成果
    • 产品基准
    • 最近的开发
  • Amgen Inc.
    • 公司概要
    • 财务实际成果
    • 产品基准
    • 最近的开发
  • Intellia Therapeutics
    • 公司概要
    • 财务实际成果
    • 产品基准
    • 最近的开发
  • Novartis International AG
    • 公司概要
    • 财务实际成果
    • 产品基准
    • 最近的开发
  • Caribou Biosciences, Inc
    • 公司概要
    • 财务实际成果
    • 产品基准
    • 最近的开发
  • Celyad
    • 公司概要
    • 财务实际成果
    • 产品基准
    • 最近的开发
  • Bellicum Pharmaceuticals, Inc.
    • 公司概要
    • 财务实际成果
    • 产品基准
    • 最近的开发
  • Noile-Immune Biotech
    • 公司概要
    • 产品基准
    • 最近的开发
  • Nanjing Legend Biotechnology Co., Ltd.
    • 公司概要
    • 产品基准
    • 最近的开发
  • Johnson & Johnson
    • 公司概要
    • 财务实际成果
    • 产品基准
    • 最近的开发
  • Sangamo Therapeutics, Inc.
    • 公司概要
    • 财务实际成果
    • 产品基准
    • 最近的开发
Product Code: PM1389

The global CAR-T cell therapy market size is expected to reach USD 188.84 billion by 2034, according to a new study by Polaris Market Research. The report "CAR-T Cell Therapy Market Size, Share, Trends, Industry Analysis Report: By Indication, Target Antigen [CD19/CD22, BCMA (B-Cell Maturation Antigen), and Others], and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Chimeric Antigen Receptor T-cell (CAR-T) therapy represents an advancement in cancer treatment, transforming immuno-oncology. The therapy offers personalized and highly effective treatment options for certain cancers, particularly hematological malignancies, by engineering a patient's T-cells to express synthetic receptors that target specific cancer antigens. The global CAR-T cell therapy market has witnessed exponential growth over the last decade, driven by rapid advancements in biotechnology, increasing approval rates of CAR-T therapies, and rising demand for innovative cancer treatments.

The increasing prevalence of cancer globally, coupled with a growing preference for precision medicine, has fueled demand for advanced treatment modalities such as CAR-T cell therapy. Moreover, supportive regulatory frameworks and rapid approval pathways have accelerated the availability of CAR-T therapies. Government and private investments in research further propel the CAR-T cell therapy market expansion.

The development of next-generation CAR-T therapies, including multi-target CAR-T cells and armored CAR-T cells, is driving the CAR-T cell therapy market growth. Multi-target CAR-T cells are engineered to recognize multiple antigens, addressing issues such as tumor heterogeneity and antigen escape, which limit the efficacy of traditional CAR-T treatments. Armored CAR-T cells are designed to overcome the immunosuppressive tumor microenvironment by secreting cytokines or other molecules to enhance anti-tumor activity.

The application of CAR-T therapy is expanding beyond oncology. Researchers are exploring its potential in treating autoimmune diseases such as lupus and multiple sclerosis and infectious diseases, including HIV. These novel applications are estimated to significantly broaden the market scope and impact.

CAR-T Cell Therapy Market Report Highlights

In terms of indication, the follicular lymphoma (FL) segment is expected to grow at the fastest pace, with a CAGR of 43.2% during the forecast period due to the rising incidence of refractory and high-risk cancer cases.

Based on target antigen, the CD19/CD22 antigen segment, valued at USD 6,258.5 billion in 2024, held the largest market share owing to its established role in treating B-cell malignancies such as diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL).

In the global market, the North America CAR-T cell therapy market held a 47.16% market share in 2024 due to the presence of advanced healthcare infrastructure, significant research and development investments, and a high prevalence of hematologic malignancies.

The Europe CAR-T cell therapy market is expected to witness a CAGR of 33.2% during the forecast period due to increased focus on expanding access to advanced therapies, coupled with the rising prevalence of relapsed or refractory hematologic cancers.

A few of the global key market players are Bluebird Bio; Celgene Corporation; Gilead Sciences; Cellectis; Servier Laboratories; Pfizer Inc.; Merck; Amgen; Intellia Therapeutics; Novartis; Caribou Biosciences; Celyad; Bellicum Pharmaceuticals, Inc.; Noile-Immune Biotech; Nanjing Legend Biotechnology Co., Ltd.; Johnson & Johnson; and Sangamo Therapeutics, Inc.

Polaris Market Research has segmented the CAR-T cell therapy market report on the basis of indication, antigen, and region:

By Indication Outlook (Revenue, USD Billion, 2020-2034)

  • DLBCL (Diffuse large B-cell lymphoma)
  • ALL (Acute Lymphoblastic Leukemia)
  • CLL (Chronic Lymphocytic Leukemia)
  • MM (Multiple Myeloma)
  • FL (Follicular Lymphoma)
  • Mastozytosis
  • Myeloid Fibrosis
  • MLL (Mixed Lineage Leukemia)
  • Thymic Cancer
  • Glioblastoma
  • AML (Acute Myeloid Leukemia)
  • Other

By Target Antigen Outlook (Revenue, USD Billion, 2020-2034)

  • CD19/CD22
  • BCMA (B-Cell Maturation Antigen)
  • Others

By Regional Outlook (Revenue, USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

Chapter 1. Introduction

  • 1.1 Report Description
    • 1.1.1 Objectives of the Study
    • 1.1.2 Market Scope
  • 1.2 Assumptions
  • 1.3 Stakeholders
  • 1.4 List of Abbreviations

Chapter 2. Executive Summary

  • 2.1 Market Highlights

Chapter 3. Research Methodology

  • 3.1 Overview
    • 3.1.1 Data Mining
  • 3.2 Data Sources
    • 3.2.1 Primary Sources
    • 3.2.2 Secondary Sources

Chapter 4. CAR-T Cell Therapy Market Insights

  • 4.1 CAR-T Cell Therapy Market Dynamics
    • 4.1.1 Drivers and Opportunities
      • 4.1.1.1 Promising growth in leukemia segment for DLBCL and Multiple Myeloma coupled with launches
      • 4.1.1.2 Potential applications in solid tumor
    • 4.1.2 Restraints and Challenges
      • 4.1.2.1 Patient Relapse
      • 4.1.2.2 Manufacturing and logistics challenges
      • 4.1.2.3 Economic model/reimbursement/scaling
  • 4.2 Porter's Five Forces Analysis
    • 4.2.1 Bargaining Power of Suppliers (High)
    • 4.2.2 Threats of New Entrants: (High)
    • 4.2.3 Bargaining Power of Buyers (Low)
    • 4.2.4 Threat of Substitute (Low)
    • 4.2.5 Rivalry among existing firms (High)
  • 4.3 PEST Analysis
  • 4.4 Timeline of CAR-T Cell Therapy Development
  • 4.5 CAR-T Cell Manufacturing Outlook
  • 4.6 Side-effects of CAR-T Cell
  • 4.7 Antigens targeting solid tumors
  • 4.8 Clinical trials Landscape for CAR-T
  • 4.9 Commercial Landscape (Mergers & Acquisitions, Partnerships & Collaborations)
  • 4.10 New Innovations in CAR-T therapies
    • 4.10.1 "Off-the-shelf" CAR-T or allogenic CAR-T
    • 4.10.2 Development of Dual CAR-T
    • 4.10.3 Development of Non-viral transcription technologies
    • 4.10.4 The advent of TIL as well as TC R therapies
      • 4.10.4.1 TCR (T-cell receptor)
      • 4.10.4.2 TIL (Tumor-Infiltrating Lymphocytes)
  • 4.11 CAR-T Cell Therapy Market - Covid Impact Analysis
  • 4.12 Customization - CAR-T Cell Market

Chapter 5. CAR-T Cell Therapy Market Assessment by Indication

  • 5.1 Introduction
  • 5.2 DLBCL
  • 5.3 ALL
  • 5.4 CLL
  • 5.5 MM
  • 5.6 FL
  • 5.7 Mastozytosis
  • 5.8 Myeloid Fibrosis
  • 5.9 MLL
  • 5.10 Thymic Cancer
  • 5.11 Glioblastoma
  • 5.12 AML
  • 5.13 Other Indications

Chapter 6. Global CAR-T Cell Therapy Market, by Target Antigen

  • 6.1 Introduction
  • 6.2 CD19/CD22
  • 6.3 BCMA
  • 6.4 Others

Chapter 7. CAR-T Cell Therapy Market Assessment by Geography

  • 7.1 Introduction
  • 7.2 CAR-T Cell Therapy Market - North America
    • 7.2.1 CAR-T Cell Therapy Market - U.S.
    • 7.2.2 CAR-T Cell Therapy Market - Canada
  • 7.3 CAR-T Cell Therapy Market - Europe
    • 7.3.1 CAR-T Cell Therapy Market - Germany
    • 7.3.2 CAR-T Cell Therapy Market - UK
    • 7.3.3 CAR-T Cell Therapy Market - France
    • 7.3.4 CAR-T Cell Therapy Market - Italy
    • 7.3.5 CAR-T Cell Therapy Market - Spain
    • 7.3.6 CAR-T Cell Therapy Market - Netherlands
    • 7.3.7 CAR-T Cell Therapy Market - Austria
  • 7.4 CAR-T Cell Therapy Market - Asia Pacific
    • 7.4.1 CAR-T Cell Therapy Market - China
    • 7.4.2 CAR-T Cell Therapy Market - India
    • 7.4.3 CAR-T Cell Therapy Market - Japan
    • 7.4.4 CAR-T Cell Therapy Market - South Korea
    • 7.4.5 CAR-T Cell Therapy Market - Australia
  • 7.5 CAR-T Cell Therapy Market - Latin America
    • 7.5.1 CAR-T Cell Therapy Market - Brazil
    • 7.5.2 CAR-T Cell Therapy Market - Mexico
  • 7.6 CAR-T Cell Therapy Market - Middle East & Africa
    • 7.6.1 CAR-T Cell Therapy Market - Saudi Arabia
    • 7.6.2 CAR-T Cell Therapy Market - UAE

Chapter 8. Competitive Landscape

  • 8.1 Product Launch and Acquisition Are the Best Adopted Strategy by the Companies
  • 8.2 Product Launch
  • 8.3 Partnerships/Collaborations/Agreements/Exhibitions

Chapter 9. Company Profiles

  • 9.1 Bluebird Bio
    • 9.1.1 Company Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Benchmarking
    • 9.1.4 Recent Development
  • 9.2 Celgene Corporation
    • 9.2.1 Company Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Benchmarking
    • 9.2.4 Recent Development
  • 9.3 Gilead Sciences, Inc.
    • 9.3.1 Company Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Benchmarking
    • 9.3.4 Recent Development
  • 9.4 Cellectis
    • 9.4.1 Company Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Benchmarking
    • 9.4.4 Recent Development
  • 9.5 Servier Laboratories
    • 9.5.1 Company Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Benchmarking
    • 9.5.4 Recent Development
  • 9.6 Pfizer Inc.
    • 9.6.1 Company Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Benchmarking
    • 9.6.4 Recent Development
  • 9.7 Merck KGaA
    • 9.7.1 Company Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Benchmarking
    • 9.7.4 Recent Development
  • 9.8 Amgen Inc.
    • 9.8.1 Company Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Benchmarking
    • 9.8.4 Recent Development
  • 9.9 Intellia Therapeutics
    • 9.9.1 Company Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Benchmarking
    • 9.9.4 Recent Development
  • 9.10 Novartis International AG
    • 9.10.1 Company Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Benchmarking
    • 9.10.4 Recent Development
  • 9.11 Caribou Biosciences, Inc
    • 9.11.1 Company Overview
    • 9.11.2 Financial Performance
    • 9.11.3 Product Benchmarking
    • 9.11.4 Recent Development
  • 9.12 Celyad
    • 9.12.1 Company Overview
    • 9.12.2 Financial Performance
    • 9.12.3 Product Benchmarking
    • 9.12.4 Recent Development
  • 9.13 Bellicum Pharmaceuticals, Inc.
    • 9.13.1 Company Overview
    • 9.13.2 Financial Performance
    • 9.13.3 Product Benchmarking
    • 9.13.4 Recent Development
  • 9.14 Noile-Immune Biotech
    • 9.14.1 Company Overview
    • 9.14.2 Product Benchmarking
    • 9.14.3 Recent Development
  • 9.15 Nanjing Legend Biotechnology Co., Ltd.
    • 9.15.1 Company Overview
    • 9.15.2 Product Benchmarking
    • 9.15.3 Recent Development
  • 9.16 Johnson & Johnson
    • 9.16.1 Company Overview
    • 9.16.2 Financial Performance
    • 9.16.3 Product Benchmarking
    • 9.16.4 Recent Development
  • 9.17 Sangamo Therapeutics, Inc.
    • 9.17.1 Company Overview
    • 9.17.2 Financial Performance
    • 9.17.3 Product Benchmarking
    • 9.17.4 Recent Development

List of Tables

Table 1 Selected significant catalysts in CAR-T

Table 2 Various antigen targets are investigated for solid tumors

Table 3 Top Developers in CAR T cell clinical trials (September 2019)

Table 4 Catalyst for Small Players

Table 5 Selected deals and partnerships

Table 6 Cost of production (Lentivirus), 2022, (USD Billion)

Table 7 Cost of production (Plasmid), 2022, (USD Billion)

Table 8 Reimbursement amounts for CAR-T therapies per region, 2022, (USD Billion)

Table 9 Global CAR-T Cell Therapy Market, by Indication, 2020-2034, (USD Billion)

Table 10 Global CAR-T Cell Therapy Market, by DLBCL, 2020-2034, (USD Billion)

Table 11 Global CAR-T Cell Therapy Market, by ALL, 2020-2034, (USD Billion)

Table 12 Global CAR-T Cell Therapy Market, by CLL, 2020-2034, (USD Billion)

Table 13 Global CAR-T Cell Therapy Market, by MM, 2020-2034, (USD Billion)

Table 14 Global CAR-T Cell Therapy Market, by FL, 2020-2034, (USD Billion)

Table 15 Global CAR-T Cell Therapy Market, by Mastozytosis, 2020-2034, (USD Billion)

Table 16 Global CAR-T Cell Therapy Market, by Myeloid Fibrosis, 2020-2034, (USD Billion)

Table 17 Global CAR-T Cell Therapy Market, by MLL, 2020-2034, (USD Billion)

Table 18 Global CAR-T Cell Therapy Market, by Thymic Cancer, 2020-2034, (USD Billion)

Table 19 Global CAR-T Cell Therapy Market, by Glioblastoma, 2020-2034, (USD Billion)

Table 20 Global CAR-T Cell Therapy Market, by AML, 2020-2034, (USD Billion)

Table 21 Global CAR-T Cell Therapy Market, by Other Indications, 2020-2034, (USD Billion)

Table 22 Global CAR-T Cell Therapy Market, By Target Antigen, 2015 - 2026 (USD Billion)

  • Table 23 Global CAR-T Cell Therapy Market, by CD19/CD22, by Region, 2020-2034, (USD Billion)
  • Table 24 Global CAR-T Cell Therapy Market, by BCMA, 2020-2034, (USD Billion)
  • Table 25 Global CAR-T Cell Therapy Market, by Others, 2020-2034, (USD Billion)

Table 26 CAR-T Cell Therapy Market Assessment, By Geography, 2020-2034, (USD Billion)

Table 27 North America: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 28 North America: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 29 U.S.: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 30 U.S.: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 31 Canada: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 32 Canada: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 33 Europe: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 34 Europe: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 35 Germany: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 36 Germany: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 37 UK: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 38 UK: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 39 France: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 40 France: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 41 Italy: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 42 Italy: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 43 Spain: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 44 Spain: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 45 Netherlands: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 46 Netherlands: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 47 Austria: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 48 Austria: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 49 Asia Pacific: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 50 Asia Pacific: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 51 China: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 52 China: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 53 India: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 54 India: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 55 Japan: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 56 Japan: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 57 South Korea: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 58 South Korea: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 59 Australia: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 60 Australia: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 61 Latin America: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 62 Latin America: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 63 Brazil: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 64 Brazil: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 65 Mexico: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 66 Mexico: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 67 Middle East & Africa: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 68 Middle East & Africa: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 69 Saudi Arabia: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 70 Saudi Arabia: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 71 UAE: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 72 UAE: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

  • List of Figures
  • Figure 1. Market Highlights
  • Figure 2. Research Methodology: Top Down & Bottom Up Approach
  • Figure 3. Porter's Five Forces
  • Figure 4. CAR-T Timelines
  • Figure 5. CAR-T manufacturing process of Kymriah (Novartis)
  • Figure 6. Market by Indication
  • Figure 7. Market by Target Antigen